Ezatiostat

Ezatiostat (TER199 free base; TLK199) is a tripeptide analog of glutathione and is a selective and orally active glutathione S-transferase P1-1 (GSTP1) inhibitor. Ezatiostat leads to JNK activation by inhibiting GSTP1. Ezatiostat stimulates both lymphocyte production and bone marrow progenitor proliferation. Ezatiostat has the potential for myelodysplastic syndrome (MDS) treatment[1][2].

Product Specifications

CAS Number

[168682-53-9]

Product Name Alternative

TER199 (free base) ; TLK199

UNSPSC

12352209

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Glutathione S-transferase

Type

Peptides

Related Pathways

Apoptosis; Metabolic Enzyme/Protease

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ezatiostat.html

Purity

99.82

Solubility

DMSO : 100 mg/mL (ultrasonic) |Ethanol : ≥ 100 mg/mL

Smiles

O=C(OCC)[C@@H](C1=CC=CC=C1)NC([C@@H](NC(CC[C@H](N)C(OCC)=O)=O)CSCC2=CC=CC=C2)=O

Molecular Formula

C27H35N3O6S

Molecular Weight

529.65

Precautions

H302, H315, H319, H335

References & Citations

[1]Galili N, et al. Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome. J Hematol Oncol. 2012 May 6;5:20|[2]Ruscoe JE, et al. Pharmacologic or genetic manipulation of glutathione S-transferase P1-1 (GSTpi) influences cell proliferation pathways. J Pharmacol Exp Ther. 2001 Jul;298 (1) :339-45.

Shipping Conditions

Blue Ice

Storage Conditions

-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

Scientific Category

Peptides

Clinical Information

Phase 2

Citation 01

Adv Sci (Weinh) . 2023 Mar;10 (7) :e2205262.|Arch Biochem Biophys. 2024 Jul:757:110043.|Cell Res. 2018 Dec;28 (12) :1171-1185. |Free Radic Biol Med. 2024 Jun 19:S0891-5849 (24) 00531-8.|Phytomedicine. 2024 Aug 31:134:155989.|Redox Biol. 2023 May:61:102635.|Redox Biol. 2024 Aug 20:76:103323.|Cancer Biomark. 2025 Oct;42 (10) :18758592251390145.